Stay up-to-date on our latest news.
Nov 03, 2020
CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensureSep 25, 2020
Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine ProgramSep 25, 2020
Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine CandidateJul 08, 2020
CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidateJun 19, 2020
Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine CandidateJun 08, 2020
GL Ventures Completes $24 Million Series B-2 Investment in Clover BiopharmaceuticalsApr 27, 2020
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian SubsidiaryMar 24, 2020
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 AdjuvantFeb 24, 2020
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant SystemFeb 10, 2020
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients